Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 6:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 51 matching trials from the live ClinicalTrials.gov search.
Conditions
Alzheimer s Disease
Interventions
VY1706 Low dose, VY1706 Mid dose, VY1706 High Dose, Anti-AAV9 Total Antibody (TAb) Assay
Drug · Device
Lead sponsor
Voyager Therapeutics
Industry
Eligibility
30 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Maitland, Florida
Conditions
Alzheimer s Disease, Mild Cognitive Impairment, Healthy
Interventions
18F-PF974, 18F-florbetaben
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
50 Years to 100 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Recruiting Not applicable Interventional Accepts healthy volunteers

Mindfulness for Cognition in Early-stage Alzheimer's Disease

NCT06792877
Conditions
Mild Cognitive Impairment (MCI), Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, TBI (Traumatic Brain Injury), Aging, Healthy Elderly, Alzheimer&Amp;Amp;#39;s Dementia (AD)
Interventions
Mindfulness Intervention, Waitlist then mindfulness
Behavioral
Lead sponsor
VA Boston Healthcare System
Federal
Eligibility
50 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Healthy Volunteer Study
Interventions
Xenon gas inhalation
Drug
Lead sponsor
General Biophysics LLC
Industry
Eligibility
55 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Alzheimer Disease (AD)
Interventions
Protollin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
60 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Alzheimer&Amp;#39;s Disease-related Dementia, Alzheimer Disease, rTMS Stimulation
Interventions
Brain Stimulation
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
65 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Alzheimer Disease and Related Dementias
Interventions
Dementia Care Management Checklist for Hospice Transitions
Behavioral
Lead sponsor
New York University
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Completed No phase listed Observational Accepts healthy volunteers

Early Markers of Cognitive Change and Alzheimer s Disease

NCT01867346
Conditions
Alzheimer's Disease
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
60 Years and older
Enrollment
2,850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Healthy, Alzheimer Disease
Interventions
VG-3927, Placebo
Drug
Lead sponsor
Vigil Neuroscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Maitland, Florida • Miami, Florida
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Exendin-4 SC, Placebo SC
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
60 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Recruiting Phase 1Phase 2 Interventional

Rifaximin SSD in Dementia Trial

NCT06718686
Conditions
Dementia Alzheimer Type, Dementia Associated With Cerebrovascular Disease
Interventions
Rifaximin SSD 40 mg IR tablet, Placebo
Drug
Lead sponsor
Jasmohan Bajaj
Federal
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Alzheimer s Disease, MCI With Increased Risk for Alzheimer Disease
Interventions
Ultrasonic Debris Clearance, sham
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Stanford, California
Conditions
Alzheimer's Disease
Interventions
Active Comparator: A, Placebo Comparator B, Active Comparator B, Placebo Comparator A
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Garden Grove, California • San Francisco, California • Orlando, Florida + 5 more
Conditions
Alzheimer s Disease
Interventions
Terazosin (Hytrin), Placebo
Drug · Other
Lead sponsor
Qiang Zhang
Other
Eligibility
50 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Arterial Stiffness, White Matter Lesions, Cognitive Decline
Interventions
S-equol, Placebo
Drug
Lead sponsor
Akira Sekikawa
Other
Eligibility
65 Years to 85 Years
Enrollment
369 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia • Winston-Salem, North Carolina • Pittsburgh, Pennsylvania
Completed Phase 1Phase 2 Interventional Results available

S-Equol in Alzheimer's Disease 2 Trial

NCT03101085
Conditions
Alzheimer Disease
Interventions
S-equol and Placebo, Placebo and S-equol
Drug
Lead sponsor
Russell Swerdlow
Other
Eligibility
50 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Fairway, Kansas • Kansas City, Kansas
Conditions
Alzheimer Dementia, Dementia, Alzheimer Dementia (AD), Alzheimer, Alzheimer s Disease
Interventions
Low Dose Radiation Therapy
Radiation
Lead sponsor
Evan Thomas
Other
Eligibility
50 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Winter Park, Florida
Conditions
Alzheimer s Disease, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, Mild Dementia
Interventions
repetitive transcranial magnetic stimulation (rTMS), sham repetitive transcranial magnetic stimulation rTMS
Device · Other
Lead sponsor
Chi-Ying (Roy) Lin
Other
Eligibility
55 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Conditions
Alzheimer&Amp;#39;s Disease, Other Dementias
Interventions
Active tDCS paired with active online chair yoga
Device
Lead sponsor
University of Arizona
Other
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Tucson, Arizona
Recruiting No phase listed Observational Accepts healthy volunteers

Tau Networks in Psychotic Alzheimer's Disease

NCT05847192
Conditions
Alzheimer Disease, Alzheimer Disease With Delusions, Alzheimer Disease With Psychosis
Interventions
[18F]-PI2620 PET scan
Diagnostic Test
Lead sponsor
Northwell Health
Other
Eligibility
65 Years to 85 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Manhasset, New York
Terminated Phase 3 Interventional Results available

Phase 3 IGIV, 10% in Alzheimer´s Disease

NCT01524887
Conditions
Alzheimer´s Disease
Interventions
Immune Globulin Intravenous (Human), 10% Solution, Human albumin 0.25%
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
50 Years to 89 Years
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 34 more
Recruiting No phase listed Observational Accepts healthy volunteers

Alzheimer"s Imaging Biomarkers in Obesity

NCT05077579
Conditions
Alzheimer Disease, Obesity, Metabolic Disease
Interventions
Not listed
Lead sponsor
Cyrus A Raji
Other
Eligibility
40 Years to 60 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Alzheimer´s Disease
Interventions
Lanabecestat, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
55 Years to 85 Years
Enrollment
2,218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
77
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 58 more
Conditions
Financial Hardship, Alzheimer's Disease (AD), Alzheimer's Disease and Related Dementia (ADRD)
Interventions
Not listed
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2,460 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Seattle, Washington